Bliss GVS Pharma Ltd
NSE:BLISSGVS
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| IN |
|
Bliss GVS Pharma Ltd
NSE:BLISSGVS
|
19B INR |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
964.4B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
572.6B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
284.4B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
297.7B USD |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
217.3B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
228.9B CHF |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
151.1B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
120.9B USD |
Loading...
|
Market Distribution
| Min | -153 833.3% |
| 30th Percentile | 2.7% |
| Median | 7.3% |
| 70th Percentile | 13.2% |
| Max | 9 977% |
Other Profitability Ratios
Bliss GVS Pharma Ltd
Glance View
Bliss GVS Pharma Ltd. engages in the development, manufacture, and marketing of pharmaceutical formulations. The company is headquartered in Mumbai, Maharashtra and currently employs 750 full-time employees. The company went IPO on 2010-07-26. The firm offers a range of suppositories, tablets, suspensions and injections to various therapeutic segments, including antimalarial, antifungal, dermatological, contraceptive, laxative, anti-hemorrhoidal, antispasmodic, antibiotic, antimicrobial antipyretic, analgesic and anti-inflammatory. The firm's pharma products include capsules, creams, gels, ointments, dry powder for injection, effervescent tablets, eye/ear drops, nasal solution, lotions, lozenges, soft gelatin capsules and syrups. its other healthcare products include balm, nasal inhaler, solution, soap, vaginal wash, roll on, shampoo, powder, spray and petroleum jelly. The firm offers its products under various brands, which include Lonart, Funbact, P-Alaxin, Lofnac, Amoxicillin, Antiderm Extra Plus and Esmazole. Its product portfolio comprises over 250 branded formulations across 20 therapeutic segments.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Bliss GVS Pharma Ltd is 10.7%, which is below its 3-year median of 12.9%.
Over the last 3 years, Bliss GVS Pharma Ltd’s Operating Margin has increased from 3.5% to 10.7%. During this period, it reached a low of 3.5% on Sep 30, 2022 and a high of 16.8% on Jun 30, 2024.
